-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $14

Benzinga·05/08/2026 00:12:11
Listen to the news
Chardan Capital analyst Geulah Livshits maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and lowers the price target from $16 to $14.